The research, led by Iwan Paolucci and colleagues at The University of Texas MD Anderson Cancer Center, tackled a deceptively simple question: how much do the errors built into ablation confirmation software distort the margins we think we are measuring? The concept of an A0 ablation—analogous to the R0 resection in surgery—demands complete tumor coverage with a pre-specified margin, conventionally at least 5 millimeters, and a correspondingly low risk of local tumor progression. But because the tumor is destroyed in situ, the true margin can never be measured histologically. Instead, clinicians rely on an imaging-based surrogate: they co-register pre-ablation and post-ablation scans, contour the tumor and the ablation zone, and compute the shortest three-dimensional distance between them. Every step of that pipeline introduces error, and until now there has been no systematic way to quantify how those errors propagate into the margin threshold that should actually be required.

The team built a mathematical and computational framework that models the entire measurement chain. They identified five key sources of inaccuracy from the literature—image resolution, segmentation error, registration error, tissue deformation, and image artifacts—and folded the last two into related parameters. Segmentation error, the mismatch between a drawn contour and the true boundary of the tumor or ablation zone, was modeled as random noise added to the contours, with tumor and ablation errors treated as independent. Registration error, the misalignment introduced when the two scans are aligned, was modeled as a shift of the ablation zone with a normally distributed magnitude and a random direction along the X, Y, or Z axis. Slice thickness, which ranges from 1 to 5 millimeters in published ablation confirmation studies, was simulated by resampling the synthetic images at different resolutions in the cranio-caudal direction, since in-plane resolution is typically already below 1 millimeter.

Crucially, the researchers also incorporated two biological effects that no imaging system can capture. The first is tissue shrinkage: microwave ablation causes radial contraction of tissue, with ex vivo experiments in bovine liver reporting contraction of up to 40 percent, an upper bound likely inflated by the absence of blood perfusion. Shrinkage within the ablation zone can make the measured margin appear larger than it truly is, and the exact contraction for any individual tumor cannot be observed during the procedure. The second effect is the presence of microscopic satellite lesions—tiny tumor deposits adjacent to the main lesion that fall below the roughly 1-millimeter spatial resolution of cross-sectional imaging. The model assumed these satellites are directly adjacent to the tumor, with sizes uniformly distributed between 0.5 and 2.5 millimeters, and with their presence governed by a binomial probability. Both effects bias the observed margin upward, meaning the measured number can flatter a treatment that has actually fallen short.

The scale of the simulation was enormous: 10,000 individual simulations for each of 1,500 parameter permutations, totaling 15 million synthetic ablation scenarios. In each run, the framework sampled a tumor size and margin, generated synthetic images of the tumor and ablation zone, applied tissue shrinkage and satellite lesions, measured the true margin, then applied registration error, segmentation noise, and slice-thickness resampling before measuring the observed margin. For each parameter combination, a logistic regression was fitted across observed margins ranging from minus 5 to plus 10 millimeters, and the A0 threshold was defined as the observed margin at which the probability of true complete microscopic tumor coverage reached at least 99 percent. The entire framework was implemented in Python and packaged into a freely available web application, allowing clinicians to enter the technical specifications of their own ablation confirmation software and obtain a software-specific A0 threshold.

The results carry a clear hierarchy of blame. Segmentation error emerged as the single most influential factor: with segmentation errors of 1, 3, and 5 millimeters, the required A0 thresholds rose to 3.4, 5.2, and 8.4 millimeters respectively. Registration error followed closely, with thresholds of 3.4, 4.9, and 7.0 millimeters for registration errors of 1, 3, and 5 millimeters. Slice thickness, by contrast, had a negligible effect, shifting the threshold by at most half a millimeter across the 1-to-5-millimeter range—a difference the authors attribute to simulation noise, since it falls below the resolution of the model itself. Among the biological effects, microscopic satellite lesions proved potent: the threshold climbed from 3.4 millimeters with no satellites to 5.8, 7.4, 7.9, and 7.7 millimeters as the probability of satellite presence rose from 25 to 100 percent. Tissue shrinkage worked in the opposite direction, lowering the required threshold from 3.4 millimeters with no shrinkage to 2.8, 2.2, and 1.8 millimeters at 10, 20, and 30 percent contraction.

The practical verdict concerns the sacred 5-millimeter rule. When both segmentation and registration errors were held at or below 3 millimeters, the simulated A0 threshold stayed at or below 5 millimeters, meaning the conventional criterion reliably guaranteed complete tumor coverage in at least 99 percent of cases. But once either error exceeded 3 millimeters, the required threshold climbed above 5 millimeters, and the standard criterion became unreliable—clinicians could believe they had achieved an adequate margin while microscopic disease survived. The study also exposed a subtle bias in the clinical literature: many retrospective studies exclude cases with visually judged registration errors above 3 millimeters before determining optimal margin thresholds. The simulations showed that this exclusion practice systematically lowers the apparent A0 threshold, and that the discrepancy grows as true registration error increases. The authors argue that studies must therefore disclose how many cases were excluded and why.

Why does this matter beyond the statistics? The minimum ablative margin has repeatedly been shown to be the most important predictor of local tumor progression after ablation, and a recent systematic review reinforced 5 millimeters as a minimum requirement while suggesting 10 millimeters as optimal. Yet the field suffers from high heterogeneity, likely driven by differences in measurement methodology and accuracy. Clinical studies capable of validating an A0 threshold for each software package are impractical: the packages evolve rapidly, and capturing the full variation in tumor sizes, margins, and errors would require sample sizes exceeding a thousand patients per comparison. Worse, the biological confounders are fundamentally unmeasurable in patients—microscopic satellites are known only probabilistically from histological studies, and tissue shrinkage only from ex vivo experiments. For rare tumor types particularly prone to satellites, such as intrahepatic cholangiocarcinoma, the necessary sample sizes are simply unattainable. In silico methods like this framework offer the only realistic route to technical validation before clinical deployment.

The authors are candid about the limitations of their approach. Tumors and ablation zones were modeled as spheres and ellipsoids, simplifications of irregular real-world anatomy. Interactions between error sources were ignored, even though a biomechanical deformable registration algorithm, for example, would likely perform worse when fed inaccurate segmentations, and intensity-based registration might suffer from the lower signal-to-noise ratio of thin-slice images. Errors were assumed to follow zero-mean normal distributions, implying no systematic bias—an assumption that may not hold for every commercial package. Registration types, whether rigid or deformable, were not distinguished because their behavior is heavily implementation-dependent. Even so, the study delivers a concrete benchmark: ablation confirmation software should achieve registration and segmentation errors of 3 millimeters or less before its 5-millimeter margin readout can be trusted. For a field increasingly reliant on artificial intelligence-driven contouring and automated margin assessment, that number is now the bar every developer, regulator, and interventional radiologist should be measuring against.

Subject of Research: Effects of measurement errors on minimum ablative margin thresholds in thermal ablation of liver tumors

Article Title: The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study

Article References: Paolucci, I., Albuquerque, J., Siddiqi, N. S., Jones, A. K., Brock, K. K., & Odisio, B. C. (2026). The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study. CVIR Oncology, 2(1), Article 1. https://doi.org/10.1007/s44343-025-00029-9

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00029-9

Keywords: thermal ablation, liver tumors, minimum ablative margin, ablation confirmation software, segmentation error, registration error, simulation study, microwave ablation, colorectal liver metastases, hepatocellular carcinoma, image guidance, A0 margin

The corn snake, a captive-bred male weighing around 500 grams, had lived for twelve years in a carefully managed glass terrarium alongside a female conspecific. His owners provided ultraviolet B lighting on a ten-hour cycle, basking areas warmed to 32 degrees Celsius, night-time temperatures of 20 degrees, and humidity between 45 and 70 percent. He was fed two adult mice every two weeks, received no calcium or vitamin supplementation, and was never subjected to winter brumation. Despite this stable routine, the snake had never been examined by a veterinarian, and no prior medical problems had been reported.

The trouble began insidiously. For four months the snake showed progressively generalized lethargy, episodes of uncoordinated winding movements, clumsy climbing attempts, and a weakening righting reflex — the instinctive ability to flip upright when turned over. He had also been anorexic for three months and losing weight. The most striking sign emerged three weeks before presentation: a progressive swelling along the dorsal surface of the middle third of his body. Ten days before the clinic visit, the snake fell from a platform in his terrarium, after which his coordination deteriorated dramatically. When a physical examination revealed an approximately 15-centimeter firm, nodular mass along the back, together with a second firm mass palpable inside the body cavity, the veterinary team knew they were dealing with something serious.

Radiographs taken under manual restraint painted a grim picture. The images revealed segmented fusion of adjacent vertebrae extending over a total length of 20 centimeters, irregular bone contours consistent with osteophyte formation and remodeling, and lysis — destructive breakdown — of vertebral processes. Additional osteolytic lesions appeared in several vertebral processes behind the main lesion, and a longitudinal soft-tissue mass with its own opacity was visible ventral to the spinal damage. In short, something was aggressively eating away at and rebuilding the snake’s backbone from the outside in.

Ultrasound examination added a crucial piece of the puzzle. Using an 11-MHz linear probe with the snake in dorsal recumbency, the clinicians identified a 4 by 1.5 by 2 centimeter irregular, moderately vascularized mass associated with the liver. Doppler imaging quantified the blood supply to the lesion, confirming it was not a simple cyst or abscess but a living, growing structure. The combination of a destructive spinal process and a liver-associated mass strongly suggested that the snake was suffering from a malignant tumor that had already seeded a distant organ.

Given the snake’s cachectic body condition, his flaccid muscle tone, his severely reduced reflexes, and the advanced stage of the spinal disease, the prognosis was judged poor to grave. The owners elected euthanasia and consented to post-mortem sampling of both masses, though they declined to release the entire carcass for a full necropsy. That decision limited the scope of the investigation, but the tissue that was recovered proved diagnostically decisive.

Histopathology revealed a paravertebral neoplasm infiltrating the adjacent musculature and extending into the vertebral bones, causing multifocal osteolysis. Within the liver, multifocal round masses of varying size showed the same infiltrative growth pattern. The tumor cells were medium-sized spindle shapes, roughly 30 to 40 micrometers long, with indistinct borders, moderate amounts of eosinophilic cytoplasm, and large eccentric nuclei bearing prominent basophilic nucleoli. The cells displayed severe anisocytosis and anisokaryosis — marked variation in cell and nuclear size — and mitotic figures appeared at a rate of two to four per high-power field, with bizarre mitoses and zones of necrosis scattered throughout. Azan trichrome staining confirmed a collagen-containing stroma woven through the neoplasm.

Immunohistochemistry was then deployed to fingerprint the tumor. Antibodies targeting vimentin produced moderate, multifocal to coalescing cytoplasmic staining in both the paravertebral mass and the liver tumors, indicating a mesenchymal origin — the hallmark of a sarcoma. Cross-reactivity controls confirmed that the antibody panel worked reliably on snake tissue: cytokeratin labeled biliary epithelium, desmin labeled skeletal muscle and vessel walls, GFAP labeled spinal cord astrocytes, and periaxin labeled peripheral nerve. Critically, the tumor cells did not express desmin, alpha-smooth muscle actin, GFAP, or periaxin, which ruled out origins from skeletal muscle, smooth muscle, or peripheral nerve sheaths. Taken together, the findings pointed to a poorly differentiated, metastasizing fibrosarcoma — most likely arising in the paravertebral tissue and secondarily invading bone, though the authors acknowledge that a primary vertebral tumor extending outward is also plausible.

The case carries broader significance for reptile medicine. Neoplastic disease in snakes appears to be reported with increasing frequency, a trend attributed to longer captive lifespans, better diagnostic services, and more informed owners bringing animals to clinics. Multi-institutional surveys have found that the vast majority of snake neoplasms — between 78 and 86.6 percent — are malignant, with soft tissue sarcomas among the most common. Musculoskeletal neoplasia, however, remains rare, accounting for only 1.4 to 4.8 percent of all tumors in snakes. Metastatic spread has been documented in reptiles, with one large study detecting metastases in 12.7 percent of reptiles with neoplastic disease, and another reporting detectable metastases in 42.9 percent of snakes with cancer. Yet ante-mortem diagnosis of metastasis is seldom reported, largely because reptile patients tend to arrive at clinics with disease already at an advanced stage, so full cancer staging is rarely performed. The authors suggest that this practice likely underestimates the true rate of metastatic tumors in snakes.

The Hannover team also emphasizes a practical lesson for clinicians: neoplasia deserves a place on the differential diagnosis list for common vertebral disorders in snakes, alongside the infectious, nutritional, and traumatic causes that are more routinely considered. Radiography and ultrasonography, they note, can be genuinely useful in detecting possible metastatic spread before death, and advanced imaging such as computed tomography or magnetic resonance imaging could offer even greater clarity in future cases. Treatment options — surgery, radiotherapy, chemotherapy — exist in the literature, but standardized cancer protocols are not yet established for any reptile species, and one survey found that only about 27 percent of snakes with neoplastic disease received any treatment at all, often because they were presented too late. For this corn snake, euthanasia was the humane endpoint. But the detailed documentation of his illness adds a valuable data point to a small but growing body of knowledge, and the authors call for more published case reports to deepen understanding of disease processes and treatment regimens in snakes — animals whose cancers, like their biology, remain full of surprises.

Subject of Research: Malignant paravertebral sarcoma with hepatic metastases in a corn snake

Article Title: Malignant paravertebral sarcoma with concurrent hepatic metastases in a corn snake (Pantherophis guttatus)

Article References: Hetterich, J., Puff, C., & Pees, M. (2025). Malignant paravertebral sarcoma with concurrent hepatic metastases in a corn snake (Pantherophis guttatus). Veterinary Oncology, 2(1), Article 32. https://doi.org/10.1186/s44356-025-00046-z

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00046-z

Keywords: corn snake, Pantherophis guttatus, sarcoma, spindle cell tumor, metastasis, vertebral disease, reptile oncology, fibrosarcoma, veterinary pathology, immunohistochemistry, herpetology, liver tumors

The research, published in CVIR Oncology, focused on patients undergoing microwave ablation, a technique in which a needle-like antenna inserted into the tumor generates electromagnetic fields that heat and coagulate cancerous tissue. Thermal ablation and transarterial chemoembolisation, known as TACE, are both mainstays of hepatocellular carcinoma treatment and are included as first-line options for selected patients in the Barcelona Clinic Liver Cancer recommendations as well as in American, Asian-Pacific and European guidelines. Ablation is generally reserved for patients with three or fewer tumors no larger than three centimeters, while TACE serves patients with larger or more numerous tumors who are ineligible for transplantation. Because survival after TACE alone remains limited, clinicians have increasingly experimented with combining the two approaches, and several studies have shown that the combination improves overall survival, progression-free survival and local tumor control compared with chemoembolisation alone. What has been missing is any consensus on the optimal sequence and timing.

Two competing strategies dominate the field. In the TACE-first approach, embolising the hepatic arterial branches before ablation reduces the so-called heat-sink effect, in which flowing blood carries heat away from the tumor and shrinks the zone of destruction; blocking that flow first can enlarge the ablation zone. The alternative is to ablate first and follow with adjuvant TACE, a strategy motivated by the peri-ablational hyperemic response. The logic is elegant: the inflamed, hyperperfused tissue ringing the ablation cavity, with its increased blood flow, vascular permeability and reduced drug resistance, could act as a delivery corridor, allowing chemoembolic material loaded with cytotoxic drugs to reach vulnerable but potentially viable tumor cells lurking at the margin. Animal models had already demonstrated the existence of this hyperemic zone, including reports of erythrocyte congestion after thermal injury, but its temporal evolution in humans had never been systematically characterized.

To fill that gap, the Swedish team enrolled 38 patients scheduled for microwave ablation of primary liver tumors or metastases between February and October 2024 at their tertiary referral centre, ultimately analyzing 34 patients evenly split between those with cirrhosis and those without. All ablations were performed under general anesthesia in the angiography suite using Medtronic Emprint HP or Amica microwave systems under ultrasound guidance, with confirmation by cone-beam computed tomography. Each patient then underwent four contrast-enhanced ultrasound examinations at fixed intervals: immediately after the procedure, and again at two, six and twenty-four hours. The technique relies on microbubble contrast agents roughly the size of red blood cells, which are injected into a peripheral vein and tracked as they course through the liver, allowing repeated perfusion assessments without the radiation burden of repeated CT scans.

The analytical approach was as important as the imaging itself. Using dedicated quantification software, the researchers compared the mean linearized signal in the hyperemic zone immediately adjacent to the ablation cavity with the signal in normal liver parenchyma at matching depths, avoiding artifacts and shadowed regions. The result was a hyperemia-to-normal-liver ratio, or HTNL, expressing how many times more intensely perfused the reactive zone was than healthy tissue. Motion compensation algorithms corrected for respiratory movement, and the width of the hyperemic rim was measured on arterial-phase images in a joint consensus reading by three board-certified radiologists blinded to clinical information and time points. Statistical comparisons against baseline used pairwise Wilcoxon signed rank tests, with each patient serving as their own control.

The numbers were striking. Immediately after ablation, the hyperemic zone was perfused at 567.5 percent of normal liver intensity in the overall group, an almost sixfold arterial oversupply, with values of 464.8 percent in cirrhotic livers and 625.0 percent in non-cirrhotic ones. That peak proved transient. By two hours the overall group’s ratio had fallen by a median of 158.9 percentage points, by six hours the drop reached 283.8 points, and at twenty-four hours it stood at 270.9 points below baseline, with all changes statistically significant. The decline was steepest in the first six hours and then leveled off, suggesting the hyperemic response collapses rapidly and then plateaus at a lower intensity. Critically, the pattern held in both cirrhotic and non-cirrhotic patients, indicating that the vascular reactivity to thermal injury operates independently of the altered hepatic hemodynamics that cirrhosis produces.

The spatial dimension of the response told the same story. The hyperemic rim measured a median of twelve millimeters wide immediately after ablation in the overall group, ten millimeters in cirrhotic patients and fourteen in non-cirrhotic ones. Over the following day it shrank steadily, narrowing by two millimeters at two hours, three at six hours and five at twenty-four hours, with parallel trends in both patient subgroups. The portal venous phase, by contrast, showed only modest enhancement, around 181.8 percent at baseline in the overall group, and no meaningful temporal decline, which the authors interpret as strong evidence that the hyperemia is supplied principally by the hepatic artery rather than the portal vein. Some portal contribution or arterial recirculation of contrast through the inflamed area cannot be excluded, but the arterial signal dwarfs everything else.

These findings carry immediate implications for trial design. Because the hyperemic zone is widest and most intensely arterialized in the first hours after ablation, an ablation-first strategy followed by TACE would plausibly need to be executed within that early window to exploit the biology. Existing evidence on sequencing remains inconclusive: one study favored ablation followed by chemoembolisation, another found no difference by order, and crucially the intervals between the two treatments varied enormously across studies, meaning any timing-dependent advantage could have been washed out. By providing high temporal resolution of the hyperemic response in humans, the Swedish data give future combination trials a concrete physiological target: the first twenty-four hours after ablation, and arguably the first six.

The authors acknowledge limitations inherent to a real-world clinical study. Ultrasound is operator-dependent, mitigated here by a small number of experienced examiners, and the consensus approach to rim measurement, while pragmatic, suppresses inter-reader variability and precludes formal reproducibility analysis. Examination times, though closely approximating the intended intervals, could not always be identical, and ablation energy and duration were chosen for treatment benefit rather than standardized, though using each patient as their own control partially offsets that. Even so, the study’s strengths, repeated quantitative imaging without radiation exposure and objective software-based perfusion measurement, make the conclusion robust: the post-ablation hyperemia is arterially supplied, peaks immediately, and fades fast. For a treatment concept that has hovered between promise and practice for years, the clock has now been set, and the race to deliver drugs into that glowing ring of healing liver may finally have a schedule.

Subject of Research: Temporal characterization of peri-ablational hyperemia after microwave ablation of liver tumors using quantitative contrast-enhanced ultrasound

Article Title: Quantitative analysis of peri-ablational hyperemia after microwave ablation of liver tumors – exploring the timing for future combination therapies

Article References: Norström Svensson, M., Will, L., Östrand, E., Sartor, H., Tingstedt, B., Andersson, B., & Baubeta, E. (2026). Quantitative analysis of peri-ablational hyperemia after microwave ablation of liver tumors – exploring the timing for future combination therapies. CVIR Oncology, 2(1), Article 8. https://doi.org/10.1007/s44343-026-00040-8

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00040-8

Keywords: microwave ablation, peri-ablational hyperemia, hepatocellular carcinoma, transarterial chemoembolisation, contrast-enhanced ultrasound, liver tumors, thermal ablation, liver cirrhosis, combination therapy, interventional radiology, tumor ablation margin, hepatic perfusion

Radioembolization, also known as selective internal radiation therapy, involves threading tiny radioactive microspheres through the arteries that feed liver tumors, delivering high doses of radiation directly to cancerous tissue while sparing healthy liver. The field has steadily moved toward increasingly selective strategies, with radiation segmentectomy now often favored over whole-liver or lobar approaches because it can treat early hepatocellular carcinoma in an ablative manner. But greater selectivity comes at a price: when a patient has multiple tumors in different liver segments, physicians frequently need to access several separate injection positions within the arterial network, and each repositioning step creates a practical dilemma that has long frustrated operators.

The problem is fundamentally one of contamination. Conventional microcatheters have a single lumen that serves both as the guidewire track and the injection channel. Once radioactive microspheres have passed through that channel, any subsequent manipulation of a guidewire through the same space risks smearing radioactive material onto the wire and, by extension, the sterile field. Current clinical practice therefore mandates discarding the microcatheter after each injection position and inserting a fresh one for the next target vessel. That approach generates additional radioactive waste, extends procedure time, and adds cost, particularly in complex cases where selective catheterization is technically demanding.

The Utrecht team hypothesized that a catheter with two physically separate lumens could eliminate this risk entirely. They employed a 3.2-Fr dual-lumen microcatheter, the Sasuke device from Asahi Intecc in Japan, which was originally designed for cardiac interventions. The device features a rapid-exchange lumen extending from the catheter tip to an exit port located 20 centimeters proximally, which accommodates a 0.016-inch guidewire, and an over-the-wire lumen that runs from the proximal catheter end to an exit port just 6.5 millimeters from the tip, which serves as the microsphere injection pathway. Because the guidewire and the microspheres travel through entirely separate channels, they never come into contact, theoretically eliminating guidewire contamination regardless of how many times the catheter is repositioned.

The technique itself unfolds in a deliberate sequence. After standard femoral arterial access with a 6-Fr sheath, a 6-Fr guiding catheter was advanced into the celiac trunk, since the 3.2-Fr microcatheter is too large to pass through standard 4 to 5 Fr diagnostic catheters. The dual-lumen microcatheter was then navigated to the first target vessel over the guidewire. Once the position was confirmed, the guidewire was retracted so that its tip resided safely within the rapid-exchange lumen, well away from any microspheres. Two microsphere administration systems were connected to the injection lumen through a three-way stopcock, the first dose was delivered, and the lumen was thoroughly flushed with saline. To move to the second site, the guidewire was simply advanced again through its dedicated lumen to steer the catheter to the next target, retracted once more, and the second dose was injected through the same channel.

The first patient was an 80-year-old man with two hepatocellular carcinoma lesions, one in liver segment 4 and one in segment 8, undergoing radioembolization work-up. The dual-lumen microcatheter successfully delivered scout doses of holmium-166 microspheres to both positions, first through the left hepatic artery and then, after repositioning, through the segment 8 artery. Cone-beam computed tomography from both positions demonstrated the expected vascular territories, and subsequent single-photon emission computed tomography confirmed adequate microsphere distribution to both tumors. The total procedure, from vascular access to closure, took 95 minutes, with cumulative fluoroscopy time of 18 minutes and 50 seconds and a total dose-area product of 330 Gy·cm².

The second case put the technique to a therapeutic test. A 79-year-old patient with neuroendocrine tumor liver metastases required treatment doses at two positions, the right hepatic artery and the segment 4 artery. Using a single dual-lumen microcatheter, the team delivered a first therapeutic dose of 4100 MBq of holmium-166 microspheres into the right hepatic artery and then repositioned to deliver a second dose of 3000 MBq into the segment 4 artery. One technical wrinkle emerged: at both injections, pressure inside the administration system rose rapidly to its maximum, indicated by the fluid level in the V-vial climbing to the rubber septum, so the team injected at a substantially reduced rate with roughly 20 seconds of additional time between flushing and microsphere administration to allow pressure normalization. A calibrated dose calibrator confirmed no significant residual activity afterward, and post-procedural imaging verified adequate microsphere distribution. This procedure took just 65 minutes, with 14 minutes and 29 seconds of fluoroscopy and a dose-area product of 86.3 Gy·cm².

Critically, radiation safety monitoring validated the central premise of the approach. As part of standard institutional protocol, all disposable materials, including the guidewire, were surveyed with a contamination monitor after each procedure. In both cases, count rates fell below the institutional threshold of 200 counts per second, the level below which materials can be discarded as regular non-radioactive waste. Catheter repositioning in both procedures was accomplished smoothly without technical difficulties, suggesting that maintaining the guidewire within its own lumen throughout the procedure neither impedes navigation nor compromises delivery precision.

The researchers are candid about the technique’s limitations. The 3.2-Fr outer diameter exceeds the typical 2.7-Fr profile of standard microcatheters, requiring guiding catheters rather than conventional diagnostic ones, a setup change that some centers may need to make. The injection port sits 6.5 millimeters proximal to the catheter tip, meaning the tip must be advanced slightly beyond the intended injection point, which could prove difficult in small vessels, and the protruding tip could theoretically pick up surface contamination. More significantly, the narrow 0.016-inch inner diameter of each lumen generates higher injection pressures than standard microcatheters, and not all microsphere delivery systems tolerate this. The instructions for use of widely used yttrium-90 glass and resin microsphere systems recommend minimum inner diameters of 0.020 and 0.021 inches respectively, making pressure compatibility an important barrier to broader adoption.

Two complementary developments could ease that constraint. Pressure-resistant delivery systems, such as the recently introduced SIROS system for yttrium-90 resin microspheres, may better accommodate narrow-lumen catheters; in a retrospective study of 48 SIROS administrations through a microcatheter with a 0.021-inch inner diameter, mean residual activity was just 4.9 percent, and 94 percent of administrations retained less than 10 percent residual activity with a double-flush protocol. Alternatively, manufacturers could design dual-lumen catheters specifically for microsphere delivery, with a larger dedicated injection lumen and a smaller guidewire channel. The authors also note that delivering predetermined doses at multiple positions currently requires multiple administration systems connected via stopcocks, and point to dose-titration systems such as the Eye90 microsphere platform as potential solutions. Guidewireless steerable microcatheters offer another route around contamination, having achieved guidewire-free catheterization in 93 percent of applications in a 50-patient multicenter trial, but they carry elevated risks of vessel injury and catheter kinking, particularly in tortuous or very wide vessels. The dual-lumen approach retains guidewire support throughout, trading a slightly larger catheter profile for potentially safer navigation.

For now, the findings rest on just two cases performed by a single experienced operator at one institution, without a control group for comparison, so the authors caution that the results do not yet support routine clinical use. Still, the proof of principle is compelling: a single catheter served two injection positions in each patient, no guidewire contamination was detected, and the technique could plausibly cut radioactive waste and procedure time in multi-position treatments. The team, whose work is supported by the European Union-funded IMAGIO consortium under the Innovative Health Initiative, calls for larger studies evaluating the technique with different microspheres and delivery systems, assessing its applicability to more complex multi-position procedures, and directly comparing repositioning time, total procedure duration, and residual activity against conventional single-lumen catheter exchange. If those studies bear out the promise, a device borrowed from the cardiology catheterization lab may become a quiet workhorse of precision liver cancer therapy.

Subject of Research: Dual-lumen microcatheter technique for multi-position radioembolization of liver tumors

Article Title: Dual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle

Article References: Smits, M. L. J., Wijnen, N., Lam, M. G. E. H., de Bruijne, J., & Vonken, E.-J. P. A. (2026). Dual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle. CVIR Oncology, 2(1), Article 28. https://doi.org/10.1007/s44343-026-00055-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00055-1

Keywords: dual-lumen microcatheter, radioembolization, guidewire contamination, holmium-166 microspheres, radiation segmentectomy, liver tumors, interventional radiology, hepatocellular carcinoma, microsphere delivery, catheter repositioning, Dual-lumen, microcatheter